Evaluating Differences of Erosion Patterns in Natural and Anthropogenic Basins through Scenario Testing: A Case Study of the Claise, France and Nahr Ibrahim, Lebanon

This study assessed soil erosion risks of two basins representing different geographical, topographical, climatological and land occupation/management settings. A comparison and an evaluation of site-specific factors influencing erosion in the French Claise and the Lebanese Nahr Ibrahim basins were performed. The Claise corresponds to a natural park with a flat area and an oceanic climate, and is characterized by the presence of 2179 waterbodies (mostly ponds) considered as hydro-sedimentary alternating structures, while Nahr Ibrahim represents an orographic Mediterranean basin characterized by a random unequal land occupation distribution. The Claise was found to be under 12.48% no erosion (attributed to the dense pond network), 65.66% low, 21.68% moderate and 0.18% high erosion risks; while Nahr Ibrahim was found to be under 4, 39.5 and 56.4%, low, moderate and high erosion risks, along with 66% land degradation determined from the intersection of land capability and land occupation maps. Under the alternative scenario for the Claise where ponds were considered dried, erosion risks became 1.12, 0.52, 76.8 and 21.56%, no erosion, low, moderate and high risks, respectively. For Nahr Ibrahim, and following the Land Degradation Neutrality intervention, high erosion risks decreased by 13.9%, while low and moderate risks increased by 3 and 10.8%

Rhinitis associated with asthma is distinct from rhinitis alone: TARIA‐MeDALL hypothesis

Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis.info:eu-repo/semantics/publishedVersio

Assessing the Impact of Man–Made Ponds on Soil Erosion and Sediment Transport in Limnological Basins

The impact of ponds on basins has recently started to receive its well-deserved scientific attention. In this study, pond-induced impacts on soil erosion and sediment transport were investigated at the scale of the French Claise basin. In order to determine erosion and sediment transport patterns of the Claise, the Coordination of Information on the Environment (CORINE) erosion and Soil and Water Assessment Tool (SWAT) models were used. The impact of ponds on the studied processes was revealed by means of land cover change scenarios, using ponded versus pondless inputs. Results show that under current conditions (pond presence), 12.48% of the basin corresponds to no-erosion risk zones (attributed to the dense pond network), while 65.66% corresponds to low-erosion risk, 21.68% to moderate-erosion risk, and only 0.18% to high-erosion risk zones. The SWAT model revealed that ponded sub-basins correspond to low sediment yields areas, in contrast to the pondless sub-basins, which yield appreciably higher erosion rates. Under the alternative pondless scenario, erosion risks shifted to 1.12%, 0.52%, 76.8%, and 21.56% for no, low, moderate, and high-erosion risks, respectively, while the sediment transport pattern completely shifted to higher sediment yield zones. This approach solidifies ponds as powerful human-induced modifications to hydro/sedimentary processes

A GIS framework for the application of the land degradation neutrality concept in Mediterranean landscapes

Given the absence of soil loss indicators within the Land Degradation Neutrality (LDN) framework, this study integrates land cover suitability, soil erosion and sediment transport as complementary Mediterranean-tailored indicators. The 309 km2 Lebanese Nahr Ibrahim basin was chosen for this purpose. Land cover suitability was determined by combining land capability-land cover maps, while soil erosion and sediment transport were assessed using the CORINE and SWAT models, respectively. Under current conditions, the following was found: a 34.84% land cover suitability; 4% low, 39.55% moderate and 56.45% high soil erosion risks zones, and 2.85% low, 26% moderate and 68.15% high sediment yields zones. Through the LDN response strategy based land use plan, land cover suitability increased by 26.54%, while soil erosion risks changed by: +3.1% low, +10.85% moderate and −18% high risk zones. For sediment transport, changes were: 0% low, +10.85% moderate and −18% high risk zones, hence the multi-effectiveness of LDN

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

© 2020 Elsevier Ltd. All rights reserved.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4·0, 95 % CI -7·7 to -0·3; phase 2 OLE patisiran -4·7, -11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1·4, 95% CI -6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran.info:eu-repo/semantics/publishedVersio